CorMedix (CRMD) Q2 2026 earnings review
Executing Through the TDAPA Cliff
CorMedix successfully navigated its most challenging quarter of the year. Sequential revenue decelerated from $127.4M in Q1 to $101.9M in Q2, but this was a manufactured dip: the company previously guided for a shelf-stock adjustment ahead of DefenCath's July 1 transition off TDAPA reimbursement. DefenCath actually beat management's internal ~$60M projection, delivering $66.1M. Despite the sequential top-line drop, management raised full-year Adjusted EBITDA guidance to $125-$140M, signaling strong confidence in underlying cost controls and cash generation from the newly acquired Melinta portfolio.
🐂 Bull Case
CorMedix signed a multi-year supply agreement with another Large Dialysis Operator (LDO), initiating a pilot in Q3. This expands their commercial footprint to all five of the top dialysis providers in the U.S., significantly expanding the addressable volume baseline.
Despite the sequential revenue drop, the company raised FY26 Adjusted EBITDA guidance. Operating cash flow remains robust, allowing the company to build a $256.7M cash war chest to fund the REZZAYO launch.
🐻 Bear Case
While Q2 survived the inventory adjustment, Q3 and Q4 face the reality of lower net selling prices as DefenCath shifts to a bundled add-on payment. Volume growth must severely accelerate to offset the price compression.
Total operating expenses jumped 87% YoY to $34.2M. While Melinta integration plays a role, R&D nearly tripled YoY, and general/administrative expenses surged 59%.
⚖️ Verdict: 🟢
Bullish. Management telegraphed the Q2 revenue dip months in advance, and the actual DefenCath sales ($66.1M) beat their internal ~$60M estimates. Securing the final Top 5 LDO and raising EBITDA guidance proves the commercial execution is on track ahead of the critical H2 reimbursement transition.
Key Themes
DefenCath Commercial Footprint Reaches 100% of Top 5 LDOs
A massive commercial win: CorMedix signed a multi-year commercial supply agreement with a new Large Dialysis Operator (LDO). The company now holds contracts with all of the top 5 dialysis providers in the U.S. market. The new LDO begins ordering and piloting in Q3, which will serve as a critical volume driver to offset the pricing pressure expected in the second half of the year.
The H2 Reimbursement Pricing Cliff
As of July 1, 2026, DefenCath's macro regulatory environment shifted. The drug transitioned off the favorable TDAPA reimbursement program and into a bundled post-TDAPA add-on adjustment. Management has historically warned this will cause 'price erosion and revenue variability' in Q3 and Q4. Investors must monitor whether the newly signed LDO volume can outpace the imminent drop in net revenue per unit.
REZZAYO sNDA Submission Timeline Locked
On the innovation front, CorMedix and partner Mundipharma finalized their timeline for REZZAYO. Following positive Phase III ReSPECT data earlier this year, the sNDA for the prophylaxis of invasive fungal disease will be submitted to the FDA in Q3 2026. Assuming acceptance, FDA action is expected in H1 2027, clearing the runway for a major product launch next year.
OpEx Spikes Contradict Synergy Narrative
Management cites 'positive underlying demand trends' and 'disciplined focus', but the expense lines tell a story of heavy spending. Operating expenses accelerated 87% YoY to $34.2M. R&D jumped from $2.4M to $6.7M due to pediatric and TPN clinical trials, and G&A surged 59% to $15.1M. Notably, G&A was only kept at $15.1M because of a one-time $4.2M insurance credit for legal fees—meaning the true operational burn rate is running even hotter than reported.
Other KPIs
Accelerating significantly from $178.1M at the end of Q1 2026 and $144.8M at the end of 2025. Strong cash generation ($128.6M operating cash flow over the first six months) provides CorMedix with a highly defensive balance sheet to weather the H2 TDAPA pricing transition and fund the commercial rollout of REZZAYO in 2027.
Stable and performing exactly as designed. Revenue from the acquired Melinta portfolio increased sequentially from $29.9M in Q1, providing a reliable, non-dialysis revenue floor that insulated the total top-line during DefenCath's Q2 inventory shelf-stock adjustment.
Decelerating from $38.6M in Q1 2026, primarily due to the drop in DefenCath sales volume. However, it represents a solid 31% YoY increase compared to Q2 2025 ($19.8M), proving the combined entity is sustainably profitable even during expected transitional quarters.
Guidance
Maintained. With $229.3M generated in H1, the midpoint ($335M) implies only ~$105.7M in revenue for the entire second half of the year. This confirms management's expectation of a severe deceleration in H2 dollar figures as DefenCath net pricing drops under the new reimbursement framework.
Accelerating. Raised from the prior range of $115 - $135 million. Despite forecasting a lower revenue run-rate in H2, the company expects to extract more profit from those dollars, likely relying on the higher-margin Melinta portfolio and realization of post-merger operational synergies.
Narrowed from the prior $145 - $160 million range. Indicates stable cost visibility for the remainder of the year, likely factoring in the incremental hires (15-20 headcount) planned for H2 2026 to prepare for the REZZAYO launch.
Key Questions
LDO Pilot Ramp-Up
With the final Top 5 LDO initiating a pilot in Q3, what is the expected timeline for converting this pilot into system-wide utilization, and what percentage of total clinic volume does this specific LDO represent?
July/August TDAPA Realities
We are now six weeks into the post-TDAPA bundled payment environment. Can you quantify the exact percentage impact on net selling price you are experiencing in Q3 compared to Q1?
G&A Expense Trajectory
General and Administrative expenses were artificially lowered by a $4.2M insurance reimbursement this quarter. Without this credit, G&A would have approached $19.3M. Is this the new normalized quarterly run-rate we should model going forward?
REZZAYO Commercial Spend
With the sNDA submission occurring in Q3, how much of the $145-$155M cash OpEx guidance is specifically allocated to pre-commercialization activities for REZZAYO, and will that spend heavily weight into Q4?